Trial Profile
A phase II study of Apatinib in hepatocellular carcinoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Mar 2017 New trial record